The future of medicine is being shaped by technology, and few companies are pushing the boundaries like GSK. In this episode, I sit down with Christopher Austin, Head of Research Technologies at GSK, to explore how AI, data science, and cutting-edge digital capabilities are revolutionizing drug discovery and development.

Chris shares how GSK is harnessing vast datasets, AI-driven insights, and genetic validation to speed up the identification of promising drug targets. We discuss how computational biology and machine learning are dramatically reducing the time it takes to develop new treatments—sometimes cutting discovery timelines in half. From selecting the right molecular designs to improving patient identification for clinical trials, technology is streamlining the entire R&D process, increasing success rates, and ultimately bringing life-saving medicines to patients faster.

We also dive into the role of generative AI in modeling diseases, designing antibodies, and optimizing clinical trials. With AI now shaping everything from drug formulation to patient recruitment, we explore what this means for the future of medicine and the ethical considerations that come with such rapid advancements.

How will AI-driven drug discovery change the pharmaceutical industry in the next decade? What challenges remain in integrating these new technologies into traditional research models? And what does all of this mean for patients and the future of healthcare? Tune in to hear how GSK is leading the charge in transforming medicine through technology.